Cardiovascular and hemodynamic effects of glucagon-like peptide-1

Adam G. Goodwill, Kieren J. Mather, Abass M. Conteh, Daniel J. Sassoon, Jillian N. Noblet, Johnathan D. Tune

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has been shown to have hemodynamic and cardioprotective capacity in addition to its better characterized glucoregulatory actions. Because of this, emerging research has focused on the ability of GLP-1 based therapies to drive myocardial substrate selection, enhance cardiac performance and regulate heart rate, blood pressure and vascular tone. These studies have produced consistent and reproducible results amongst numerous laboratories. However, there are obvious disparities in findings obtained in small animal models versus those of higher mammals. This species dependent discrepancy calls to question, the translational value of individual findings. Moreover, few studies of GLP-1 mediated cardiovascular action have been performed in the presence of a pre-existing comorbidities (e.g. obesity/diabetes) which limits interpretation of the effectiveness of incretin-based therapies in the setting of disease. This review addresses cardiovascular and hemodynamic potential of GLP-1 based therapies with attention to species specific effects as well as the interaction between therapies and disease.

Original languageEnglish
Pages (from-to)209-217
Number of pages9
JournalReviews in Endocrine and Metabolic Disorders
Issue number3
StatePublished - Sep 2014


  • Cardiovascular
  • GLP
  • Glucagon Like Peptide
  • Incretin


Dive into the research topics of 'Cardiovascular and hemodynamic effects of glucagon-like peptide-1'. Together they form a unique fingerprint.

Cite this